Abstract
Small molecules designed to specifically activate or inactivate protein functions have been useful to study biological processes. PROTACS are small molecule chimera which comprise a ligand and a peptide recognition motif for an E3 ligase. These novel reagents exploit the ubiquitin-mediated proteasome degradation pathway to target the ligand-bound protein for intracellular degradation. Here, we report that an estrogen receptor (ER)-targeting PROTACS that causes degradation of ER is able to potently inhibit endothelial cell differentiation in a three-dimensional angiogenic sprouting assay. These findings support the use of ER-targeting PROTACS as probes of angiogenesis.
Original language | English |
---|---|
Pages (from-to) | 2724-2727 |
Number of pages | 4 |
Journal | Bioorganic and Medicinal Chemistry Letters |
Volume | 15 |
Issue number | 11 |
DOIs | |
State | Published - Jun 2 2005 |
Bibliographical note
Funding Information:We are grateful to the Department of Ophthalmology and Visual Sciences (University of Kentucky) for generous start-up funds to R.M. and the Kentucky Lung Cancer Research Program for financial support to K.K.
Funding
We are grateful to the Department of Ophthalmology and Visual Sciences (University of Kentucky) for generous start-up funds to R.M. and the Kentucky Lung Cancer Research Program for financial support to K.K.
Funders | Funder number |
---|---|
Kentucky Lung Cancer Research Program | |
National Eye Institute (NEI) | R01EY016782 |
University of Kentucky |
Keywords
- Angiogenesis
- Endothelial cell differentiation
- Estrogen
- PROTACS
- Receptor
ASJC Scopus subject areas
- Biochemistry
- Molecular Medicine
- Molecular Biology
- Pharmaceutical Science
- Drug Discovery
- Clinical Biochemistry
- Organic Chemistry